Antibiotherapy - Page 3 de 7

info-atbvac > International News > Antibiotherapy

Description of slowly or non-resolving Legionnaires’ disease. ( Cécile Pouderoux et al. )

Slowly or non-resolving Legionnaires’ disease: case series and literature review.

07 mai | Dr Jean-Pierre Bru

Progress to a slowly or non-resolving form after a Legionnaires’ disease (LD) is a rare event. The aim of this … Suite

Anidulafungin and Micafungin concentrations in Cerebrospinal Fluid and in Cerebral Cortex. ( Jana Marx et al. )

Anidulafungin and Micafungin concentrations in Cerebrospinal Fluid and in Cerebral Cortex.

05 mai | Dr Jean-Pierre Bru

As penetration of caspofungin into the human central nervous system (CNS) is known to be limited, this study aimed to … Suite

Except for ICU patients, ceftolozane-tazobactam is a treatment option for multi-drug resistant P. aeruginosa. ( Jorgensen SCJ. et al )

Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

28 avr | Dr Olivier Leroy

Gram-negative bacilli and especially P. aeruginosa are responsible for increasingly multi-drug resistance challenging problems. The association between a new cephalosporin … Suite

It’s time for oral step-down therapy for the treatment of Infective Endocarditis. ( Spellberg B. et al. )

Evaluation of a Paradigm Shift From Intravenous Antibiotics to Oral Step-Down Therapy for the Treatment of Infective Endocarditis. A Narrative Review.

23 avr | Dr Jean-Pierre Bru

Most of the current guidelines for the management of infective endocarditis (IE) recommend prolonged intravenous antibiotic courses without any oral … Suite

Dalbavancin in Bone and Joint Infections. Data from a retrospective study. ( Morata L. et al. )

Safety and Efficacy of Prolonged Use of Dalbavancin in Bone and Joint Infections.

21 avr | Dr Jean-Pierre Bru

Dalbavancin is a lipoglycopeptide has a potent activity against Gram positive microorganisms, a long half-life (T1/2 160 – 240 h), … Suite

Antibiotic Exposure and Clostridioides difficile Infection: Precise quantification of risk, useful when prescribing ( Brown KA et al. )

Antibiotic prescribing choices and their comparative C. difficile infection risks: a longitudinal case-cohort study.

16 avr | Dr Philippe Lesprit

Antibiotic use is the most important risk factor for the development of Clostridioides difficile infection (CDI). CDI risk is driven … Suite

Suppressive antibiotic therapy in prosthetic joint infections. Data from real life. ( Escudero-Sanchez R. et al. )

Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study.

14 avr | Dr Jean-Pierre Bru

Suppressive antibiotic therapy (SAT) can be defined as the indefinite administration of antibiotics with the objective of reducing the patient’s … Suite

Antifungal prophylaxis appears to be necessary after lung transplantation but optimal modalities remain to be defined. ( Baker AW. et al. )

Invasive Fungal Infection After Lung Transplantation: Epidemiology in the Setting of Antifungal Prophylaxis.

07 avr | Dr Olivier Leroy

Survival following lung transplantation continues to improve. However, lung transplant recipients remain at substantial risk for the development of invasive … Suite

Is it time to administer ceftriaxone as continuous infusion in critically ill patients? ( Leegwater E. et al. )

Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients.

31 mar | Dr Jean-Pierre Bru

Ceftriaxone has a long half-life of approximately 8.5 h, owing a once daily administration. But in critically ill patients, the … Suite

Pulmonary diffusion of dalbavancin could allow its use in the treatment of pneumonia ( Rappo U. et al. )

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion.

26 mar | Dr Olivier Leroy

Pneumonia is frequently caused by gram-positive cocci including S. aureus and S. pneumoniae. Dalbavancin is effective against these pathogens and … Suite